# ATR (AptarGroup, Inc.) Stock Analysis — 2026-09-09

> AptarGroup is a high-quality, niche-dominant franchise in drug delivery and dispensing systems, with Pharma generating over two-thirds of group profits. The stock trades at $124.34, down 15.4% from its 52-week high, with an RSI of 27.9 indicating oversold conditions. Fundamentals are mixed but not b...

- Verdict: **Hold**
- Price at analysis: $124.34
- 1Y price target: $130.00 (+4.6% implied)
- 3Y price target: $142.00 (+14.2% implied)
- Technicals: RSI 28, MACD bearish
- Source: https://stockquantai.com/research/atr/2026-09-09

## Executive Summary

AptarGroup is a high-quality, niche-dominant franchise in drug delivery and dispensing systems, with Pharma generating over two-thirds of group profits. The stock trades at $124.34, down 15.4% from its 52-week high, with an RSI of 27.9 indicating oversold conditions. Fundamentals are mixed but not broken: Q2 2026 marked the first $1B+ revenue quarter ($1.03B, +6% reported) with adjusted EPS of $1.42 beating estimates by ~4%, but core sales growth was just 1% and Q1 showed margin compression (adjusted EBITDA margin of 19.2% vs 20.7%).

The bear case is real: organic growth has stalled, currency and acquisitions are doing the heavy lifting on reported growth, and a CEO transition introduces execution uncertainty. The bull case rests on secular pharma packaging tailwinds (injectables, ophthalmic, sustainability-driven demand), margin recovery potential, and a valuation (~$8.1B market cap, roughly 22-23x forward earnings) that is reasonable — not cheap — for a business of this quality.

My verdict is neutral. This is a fine company at a fair price facing a genuine organic growth deceleration that the market has already partially priced in. The oversold technicals limit near-term downside, but without core growth reacceleration there is no catalyst for meaningful multiple expansion. I expect the stock to grind higher modestly as margins stabilize, but not deliver outsized returns over 1-3 years.

## Price Targets

| Horizon | Price | Implied Growth |
|---|---|---|
| 1 Year | $130.00 | +4.6% |
| 3 Year | $142.00 | +14.2% |

## Scenarios

| Scenario | 1Y Price | 3Y Price | Thesis |
|---|---|---|---|
| Hyper Bull | $175.00 | $215.00 | Requires core sales growth reaccelerating above 5% with Pharma margin expansion driving EBITDA margins back above 21% group-wide, plus multiple re-rating to 25x+ as investors reclassify Aptar as a medtech-like drug delivery platform. FX tailwinds persist and M&A accelerates the pharma portfolio shift. This is a low-probability outcome given current flat organic trends. |
| Bull | $142.00 | $165.00 | Core sales stabilize at low-single-digit growth, EBITDA margins hold in the 21-22.5% range, and EPS reaches ~$5.80-6.00. The market rewards steady execution with a return toward the 52-week high (~$147) over 12 months, and compounding EPS growth of 6-7% annually plus dividends carries the stock to ~$165 by 2029. Oversold technicals provide a favorable entry. |
| Neutral | $130.00 | $142.00 | The most likely path: flat-to-1% core growth with modest margin stabilization produces ~$5.50-5.70 EPS. The stock oscillates between $115 and $140 as oversold conditions resolve but no organic growth catalyst emerges. Over three years, modest EPS growth and a ~2% dividend yield deliver mid-single-digit annualized returns — fair, not compelling. |
| Bear | $108.00 | $100.00 | Core sales turn negative as consumer end-markets deteriorate further, FX tailwinds reverse, and EBITDA margins slip back toward 19%. EPS falls toward $5.00, the multiple compresses to 18-19x, and the stock tests and breaks its 52-week low of $103. The CEO transition fails to reinvigorate growth. |
| Hyper Bear | $90.00 | $80.00 | Requires simultaneous pharma program delays, a European recession crushing half of revenue, margin collapse to high-teens, and multiple compression to 15x — a scenario with no support in current data given pharma's defensive characteristics. Included for completeness only. |

## Key Metrics

- Market Cap: $8.10B
- P/E Ratio: ~22-23x forward (est. ~$5.50 annualized adjusted EPS)
- P/S Ratio: ~2.0x (est. ~$4.0B annual revenue)
- Revenue: $1.03B Q2 2026 (first $1B+ quarter, +6% reported)
- Net Income: N/A (Q2 adjusted EPS $1.42)
- EPS: $1.42 Q2 2026 adjusted; $1.19 Q1 2026 adjusted
- Dividend Yield: ~2% (est.)
- Beta: N/A
- 52-Week High: $146.91
- 52-Week Low: $103.23
- Short Interest: N/A (no ATR-specific data; no elevated short thesis evident)

## Micro Analysis

AptarGroup's Q2 2026 results showed record quarterly revenue above $1B with 6% reported growth, but core sales grew only 1%, revealing reliance on FX and the Sommaplast acquisition. Q1 exposed margin pressure (EBITDA margin down 150bps YoY to 19.2%) from unfavorable product mix, while Q2 EBITDA margins recovered to 22.6%. The Pharma segment (2/3+ of profits) remains the key growth engine, supported by active-to-market drug delivery programs and the Sommaplast acquisition expanding the pharma portfolio. A smooth internal CEO transition (Gael Touya, former Pharma president) supports strategic continuity.

- **Organic growth deceleration**: Q1 core sales flat, Q2 core sales up just 1% — reported growth of 6-11% is heavily FX- and M&A-driven. This is the central fundamental problem the market is repricing.
- **Margin volatility**: Q1 adjusted EBITDA margin fell to 19.2% from 20.7% on product mix; Q2 recovered to 22.6% with EPS of $1.42 beating consensus by 3.8%. Margin stability, not expansion, is the base case.
- **Pharma segment quality**: Pharma generates over two-thirds of group profits with high switching costs and long product lifecycles; the December 2025 Sommaplast acquisition and Ophthalmic Squeeze Dispenser momentum reinforce competitive moats.
- **Leadership transition**: Internal promotion of Gael Touya (Pharma president) to CEO signals continuity, but transitions add near-term uncertainty and the stock fell ~4% on the announcement.
- **Technically oversold**: RSI of 27.9 with the stock 15.4% below its 52-week high and 20.5% above its low — downside appears partially exhausted absent a fundamental deterioration.

## Macro Analysis

Aptar's end markets are structurally supported: pharmaceutical packaging is projected to exceed $219B by 2031, cosmetic packaging to reach $61.5B by 2032 (5.76% CAGR), and pharmaceutical glass packaging to nearly double to $12.4B by 2035. With 49% of sales from Europe and 28% from the U.S., currency swings are a material reported-results driver — currently a tailwind. Consumer health demand normalization and persistent resin/pricing pressures in plastics are headwinds, but sustainability and injectable drug trends favor Aptar's premium dispensing technologies.

- **Secular pharma packaging growth**: Injectable drug packaging, smart packaging/RFID, and ophthalmic delivery are all forecast to grow above GDP through 2031-2035, directly benefiting Aptar's highest-margin segment.
- **Currency tailwind**: With ~49% of sales in Europe, the weaker dollar has inflated reported sales (Q1 +11% reported vs flat core) — a benefit that could reverse if FX shifts.
- **Consumer demand normalization**: Beauty and Closures face sluggish developed-market consumer demand; flat core sales reflect a normalizing post-COVID environment rather than share loss.
- **Sustainability regulation**: EU packaging and sustainability rules favor Aptar's recyclable and refillable dispensing innovations, creating both cost pressure and competitive differentiation.

## Revenue Opportunities

- **Injectable drug delivery systems** (potential: high): Rising demand for injectable biologics drives growth in Aptar's pharma delivery devices and specialized closures; pharma glass packaging market expected to double to $12.4B by 2035.
- **Sommaplast integration and pharma portfolio expansion** (potential: medium): December 2025 acquisition broadens Aptar's pharmaceutical packaging portfolio and cross-selling reach in fast-growing segments.
- **Premium and sustainable cosmetic dispensing** (potential: medium): Cosmetic packaging market growing at 5.76% CAGR to $61.5B by 2032; Aptar's high-performance, refillable dispensing systems are positioned in the fastest-growing premium/sustainable niches.
- **Smart packaging and RFID-enabled pharma verification** (potential: medium): Smart packaging innovation (RFID-enabled verification) in a pharma packaging market exceeding $219B by 2031 offers a differentiated growth vector.

## Headwinds

- **Stalled core/organic growth** (severity: high): Core sales were flat in Q1 and +1% in Q2 — reported growth is largely FX and acquisition driven. Without organic reacceleration, multiple expansion is unlikely.
- **Product mix margin pressure** (severity: medium): Q1 adjusted EBITDA margin fell 150bps YoY to 19.2%; mix headwinds could persist if lower-margin Beauty/Closures growth outpaces Pharma.
- **FX reversal risk** (severity: medium): With nearly half of sales in Europe, a dollar-strengthening scenario would erase the reported growth benefit and pressure translated earnings.
- **CEO transition execution risk** (severity: low): Leadership handoff to Gael Touya, while internally sourced, creates uncertainty on capital allocation and strategy continuity; the stock fell ~4% on the news.
- **Consumer end-market softness** (severity: medium): Developed-market consumer demand normalization keeps Beauty and Closures volumes sluggish, limiting upside from those segments.

## Tailwinds

- **Pharma packaging secular growth** (strength: high): Pharma packaging market projected to exceed $219B by 2031, with injectables and specialized closures growing fastest — Aptar's profit engine sits in the sweet spot.
- **Record quarterly revenue and EPS beats** (strength: medium): First-ever $1B+ quarter ($1.03B, +6%) and Q2 adjusted EPS of $1.42 beating estimates by 3.8% with 22.6% EBITDA margins demonstrate operational resilience.
- **Oversold technical setup** (strength: medium): RSI at 27.9 and the stock 15.4% off its high suggest negative sentiment is largely priced in, limiting near-term downside.
- **Sustainability-driven demand** (strength: medium): EU sustainability regulations and premium/sustainable packaging trends favor Aptar's innovative, recyclable dispensing technologies over commodity competitors.

## Disclaimer

This report was generated by an AI model and is for informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Always conduct your own research and consult a licensed financial advisor before making investment decisions.